Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06942520 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
A Phase 2 study of Diabetic Macular Edema, sponsored by Sierra Eye Associates.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06942520 is a Phase 2 study of Diabetic Macular Edema that is actively recruiting participants, run by Sierra Eye Associates. The registered enrollment target is 18 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06942520, a Phase 2 study of Diabetic Macular Edema, is actively recruiting participants, sponsored by Sierra Eye Associates.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
Conditions Studied
Interventions
- GENETIC RGX-314 Dose 1
- GENETIC RGX-314 Dose 2
- BIOLOGICAL Aflibercept (2.0 mg)
Study Locations (1)
Nevada
- Sierra Eye Associates - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06942520
The ClinicalTrials.gov registry entry for NCT06942520 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The listed sponsor is Sierra Eye Associates, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 3 interventions - of which RGX-314 Dose 1 is the first listed.
NCT06942520 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.
Frequently Asked Questions
What is clinical trial NCT06942520 about?
NCT06942520 is a clinical study titled "Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)". Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
What is the current status of trial NCT06942520?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2025-03-18. Estimated completion is 2027-12.
What conditions does trial NCT06942520 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT06942520?
The interventions under investigation include: RGX-314 Dose 1 (GENETIC), RGX-314 Dose 2 (GENETIC), Aflibercept (2.0 mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06942520?
This trial is sponsored by Sierra Eye Associates, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06942520 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
-
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.